Evidence map›Paper›PMID 40530143›Full record

ReviewTranslational cancer research2025

Ovarian cancer and malnutrition: a literature review.

Zhuyan Shao, Liying Fu, Yi Lu, Haifei Zhou, Yuyang Zhu, Tao Zhu

Abstract readReview
In one paragraph

Review in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhuyan ShaoDepartment of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Liying FuDepartment of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Yi LuDepartment of Clinical Nutrition, Zhejiang Cancer Hospital, Hangzhou, China.
Haifei ZhouDepartment of Clinical Oncology, Wenzhou Medical University, Wenzhou, China.
Yuyang ZhuSchool of The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Tao ZhuDepartment of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objective: Among gynecological malignancies, ovarian cancer is the most fatal, with surgery and chemotherapy being the primary treatment modalities. The nutritional status of patients with ovarian cancer undergoing chemotherapy after surgery remains generally poor, with 76.1% classified as severely malnourished according to the Patient-Generated Subjective Global Assessment (PG-SGA), while only 9.0% are well-nourished and do not require nutritional intervention. The high risk of nutritional decline associated with the new treatment modality, poly (ADP ribose) polymerase (PARP) inhibitors, has not received sufficient attention. This review examined the factors contributing to malnutrition in ovarian cancer, the adverse effects of malnutrition on treatment outcomes, the importance of regular nutritional screening and assessment, and potential nutritional interventions. Methods: A review of the relevant literature was conducted to analyze the prevalence of malnutrition in patients with ovarian cancer, its impact on treatment and prognosis, and the role of nutritional assessment and interventions in improving patient outcomes. Key Content and Findings: Malnutrition is highly prevalent among patients with ovarian cancer and is associated with worsened treatment side effects, reduced quality of life, and decreased survival rates. The use of PARP inhibitors may pose an additional risk for nutritional decline, but this possibility has not been sufficiently studied. Regular nutritional screening and assessment are essential for the early detection and management of malnutrition. Nutritional interventions have been investigated for their potential to support patients with ovarian cancer through treatment, but further research is needed to determine the most effective strategies. Conclusions: Malnutrition is a major concern for ovarian cancer patients, especially those receiving chemotherapy or PARP inhibitors. Regular nutritional assessment and timely interventions may improve treatment tolerance and overall prognosis. Further prospective studies and large randomized controlled trials are necessary to establish effective nutritional strategies for high-risk patients.

Indexed as

malnutritionnutritional interventionsOvarian cancerpoly (ADP ribose) polymerase inhibitors (PARP inhibitors)

Identifiers

PMID40530143
PMCPMC12169986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.